Published in N Engl J Med on December 08, 2012
RAMBLE - Rivaroxaban vs. Apixaban for Heavy Menstrual Bleeding (RAMBLE) | NCT02829957
Oral rivaroxaban versus standard therapy for the treatment of symptomatic venous thromboembolism: a pooled analysis of the EINSTEIN-DVT and PE randomized studies. Thromb J (2013) 2.21
Direct oral anticoagulants: integration into clinical practice. Postgrad Med J (2014) 1.40
Rivaroxaban and other novel oral anticoagulants: pharmacokinetics in healthy subjects, specific patient populations and relevance of coagulation monitoring. Thromb J (2013) 1.15
Approach to the new oral anticoagulants in family practice: part 1: comparing the options. Can Fam Physician (2014) 1.07
Cancer-related coagulopathy (Trousseau's syndrome): review of the literature and experience of a single center of internal medicine. Clin Exp Med (2013) 1.01
Guidance for the treatment of deep vein thrombosis and pulmonary embolism. J Thromb Thrombolysis (2016) 0.96
Treatment options for venous thromboembolism: lessons learnt from clinical trials. Thromb J (2014) 0.95
Effect of ketoconazole and diltiazem on the pharmacokinetics of apixaban, an oral direct factor Xa inhibitor. Br J Clin Pharmacol (2015) 0.92
D-dimer levels over time and the risk of recurrent venous thromboembolism: an update of the Vienna prediction model. J Am Heart Assoc (2014) 0.91
Guidance for the practical management of the direct oral anticoagulants (DOACs) in VTE treatment. J Thromb Thrombolysis (2016) 0.91
Evolving use of new oral anticoagulants for treatment of venous thromboembolism. Blood (2014) 0.90
Single- and multiple-dose pharmacokinetics, pharmacodynamics, and safety of apixaban in healthy Chinese subjects. Clin Pharmacol (2013) 0.90
The treatment of venous thromboembolism with novel oral anticoagulants: warnings and limitations. Blood Transfus (2015) 0.90
Comparative coronary risks of apixaban, rivaroxaban and dabigatran: a meta-analysis and adjusted indirect comparison. Br J Clin Pharmacol (2014) 0.89
Cancer-associated thrombosis, low-molecular-weight heparin, and the patient experience: a qualitative study. Patient Prefer Adherence (2014) 0.88
Effect of famotidine on the pharmacokinetics of apixaban, an oral direct factor Xa inhibitor. Clin Pharmacol (2013) 0.86
The evolution of anticoagulant therapy. Blood Transfus (2015) 0.86
Edoxaban: an update on the new oral direct factor Xa inhibitor. Drugs (2014) 0.86
An updated review of target-specific oral anticoagulants used in stroke prevention in atrial fibrillation, venous thromboembolic disease, and acute coronary syndromes. J Am Heart Assoc (2013) 0.86
Which patients with venous thromboembolism should receive non-vitamin K antagonist oral anticoagulants? The majority. Blood Transfus (2015) 0.85
Phase III trials of new oral anticoagulants in the acute treatment and secondary prevention of VTE: comparison and critique of study methodology and results. Adv Ther (2014) 0.85
The role of factor Xa inhibitors in venous thromboembolism treatment. Vasc Health Risk Manag (2015) 0.84
Update on Edoxaban for the Prevention and Treatment of Thromboembolism: Clinical Applications Based on Current Evidence. Adv Hematol (2015) 0.84
Considerations for long-term anticoagulant therapy in patients with venous thromboembolism in the novel oral anticoagulant era. Vasc Health Risk Manag (2016) 0.83
New oral anticoagulants for the treatment of venous thromboembolism: understanding differences and similarities. Drugs (2014) 0.82
Apixaban for the prophylaxis and treatment of deep vein thrombosis and pulmonary embolism: an evidence-based review. Ther Clin Risk Manag (2015) 0.82
Anticoagulant Treatment of Deep Vein Thrombosis and Pulmonary Embolism: The Present State of the Art. Front Cardiovasc Med (2015) 0.82
Intracranial hemorrhage risk with the new oral anticoagulants: a systematic review and meta-analysis. J Neurol (2014) 0.82
Rivaroxaban for the treatment of pulmonary embolism. Adv Ther (2013) 0.81
Pharmacokinetic and pharmacodynamic evaluation of rivaroxaban: considerations for the treatment of venous thromboembolism. Thromb J (2014) 0.81
Patient self-management of oral anticoagulation with vitamin K antagonists in everyday practice: efficacy and safety in a nationwide long-term prospective cohort study. PLoS One (2014) 0.80
Management of Venous Thromboembolisms: Part I. The Consensus for Deep Vein Thrombosis. Zhonghua Minguo Xin Zang Xue Hui Za Zhi (2016) 0.80
Expanding use of new oral anticoagulants. F1000Prime Rep (2014) 0.80
Extended Anticoagulant and Aspirin Treatment for the Secondary Prevention of Thromboembolic Disease: A Systematic Review and Meta-Analysis. PLoS One (2015) 0.79
Use of novel oral anticoagulant agents in venous thromboembolism. Cardiovasc Diagn Ther (2016) 0.79
Venous thromboembolism in Latin America: a review and guide to diagnosis and treatment for primary care. Clinics (Sao Paulo) (2016) 0.79
Venous thromboembolism in cancer patients: an underestimated major health problem. World J Surg Oncol (2015) 0.79
Extended treatment of venous thromboembolism. N Engl J Med (2013) 0.79
Apixaban Reduces Hospitalizations in Patients With Venous Thromboembolism: An Analysis of the Apixaban for the Initial Management of Pulmonary Embolism and Deep-Vein Thrombosis as First-Line Therapy (AMPLIFY) Trial. J Am Heart Assoc (2015) 0.78
Oral anticoagulants in the management of venous thromboembolism. Nat Rev Cardiol (2013) 0.78
New oral anticoagulants in the treatment of pulmonary embolism: efficacy, bleeding risk, and monitoring. Thrombosis (2013) 0.78
Role of apixaban (eliquis) in the treatment and prevention of thromboembolic disease. P T (2013) 0.78
The new oral anticoagulants for the treatment of venous thromboembolism: a new paradigm shift in antithrombotic therapy. Curr Ther Res Clin Exp (2014) 0.78
Management of venous thromboembolism: an update. Thromb J (2016) 0.78
New orally active anticoagulant agents for the prevention and treatment of venous thromboembolism in cancer patients. Ther Clin Risk Manag (2014) 0.77
Clinical utility of apixaban in the prevention and treatment of venous thromboembolism: current evidence. Drug Des Devel Ther (2014) 0.77
Venous thromboembolism: Predicting recurrence and the need for extended anticoagulation. Vasc Med (2015) 0.77
XALIA: rationale and design of a non-interventional study of rivaroxaban compared with standard therapy for initial and long-term anticoagulation in deep vein thrombosis. Thromb J (2014) 0.77
Apixaban and oral implications. J Clin Exp Dent (2015) 0.77
Direct oral anticoagulants in the treatment of venous thromboembolism, with a focus on patients with pulmonary embolism: an evidence-based review. Vasc Health Risk Manag (2014) 0.77
Guidance for the practical management of warfarin therapy in the treatment of venous thromboembolism. J Thromb Thrombolysis (2016) 0.77
Current Clinical Trials on the Use of Direct Oral Anticoagulants in the Pediatric Population. Cardiol Ther (2016) 0.77
Diagnosis and management of iliofemoral deep vein thrombosis: clinical practice guideline. CMAJ (2015) 0.77
The Italian START-Register on Anticoagulation with Focus on Atrial Fibrillation. PLoS One (2015) 0.76
Potential role of new anticoagulants for prevention and treatment of venous thromboembolism in cancer patients. Vasc Health Risk Manag (2013) 0.76
Evaluation of the effect of naproxen on the pharmacokinetics and pharmacodynamics of apixaban. Br J Clin Pharmacol (2014) 0.76
Cost-effectiveness of apixaban versus low molecular weight heparin/vitamin k antagonist for the treatment of venous thromboembolism and the prevention of recurrences. BMC Health Serv Res (2017) 0.75
The effect of apixaban on the pharmacokinetics of digoxin and atenolol in healthy subjects. Clin Pharmacol (2017) 0.75
Current state of anticoagulants to treat deep venous thrombosis. Curr Cardiol Rep (2014) 0.75
Duration of anticoagulation for venous thromboembolic events. Circulation (2014) 0.75
Five-year follow-up of pulmonary embolism under anticoaugulation: The PISA-PEET (Pulmonary Embolism Extension Therapy) study. Medicine (Baltimore) (2016) 0.75
Incidence of venous thromboembolism in France: a retrospective analysis of a national insurance claims database. Thromb J (2016) 0.75
New anticoagulants for the treatment of venous thromboembolism. J Bras Pneumol (2016) 0.75
Bleeding and clotting in hereditary hemorrhagic telangiectasia. World J Clin Cases (2015) 0.75
Multicentre randomised placebo-controlled trial of oral anticoagulation with apixaban in systemic sclerosis-related pulmonary arterial hypertension: the SPHInX study protocol. BMJ Open (2016) 0.75
Respiratory review of 2014: pulmonary thromboembolism. Tuberc Respir Dis (Seoul) (2014) 0.75
Reversal of direct oral anticoagulants in hemophilia treatment: ASH meeting 2015. Memo (2016) 0.75
Apixaban. Hosp Pharm (2013) 0.75
Potential new uses of non-vitamin K antagonist oral anticoagulants to treat and prevent stroke. Neurology (2015) 0.75
Use of novel oral anticoagulants for the treatment of venous thromboembolism and its considerations in Asian patients. Ther Clin Risk Manag (2014) 0.75
Perioperative management of oral anticoagulants: a focus on target-specific oral anticoagulants. Hosp Pract (1995) (2014) 0.75
ACP Journal Club: apixaban reduced recurrence and did not increase major bleeding in previously treated VTE. Ann Intern Med (2013) 0.75
The management of venous thromboembolism: A practical tool for the front-line clinician. Can Pharm J (Ott) (2017) 0.75
Use of ASA after warfarin for unprovoked VTE. Can Fam Physician (2013) 0.75
Safety of apixaban for venous thromboembolism prophylaxis: the evidence to date. Drug Healthc Patient Saf (2016) 0.75
Update on Anticoagulation: What the Interventional Radiologist Needs to Know. Semin Intervent Radiol (2016) 0.75
Novel Oral Anticoagulants for Venous Thromboembolism with Special Emphasis on Risk of Hemorrhagic Complications and Reversal Agents. Curr Drug ther (2016) 0.75
Perioperative venous thromboembolic disease and the emerging role of the novel oral anticoagulants: An analysis of the implications for perioperative management. Ann Card Anaesth (2015) 0.75
Thrombosis - Besieged but Poorly Understood. Front Cardiovasc Med (2014) 0.75
Differential benefit risk assessment of DOACs in the treatment of venous thromboembolism: focus on dabigatran. Drug Des Devel Ther (2015) 0.75
Theme 3: Non-invasive management of (recurrent) venous thromboembolism (VTE) and post thrombotic syndrome (PTS). Thromb Res (2015) 0.75
Unmet Needs in Anticoagulant Therapy: Potential Role of Rivaroxaban. Cardiol Res (2015) 0.75
Reducing the risk of venous thromboembolism using apixaban - patient perspectives and considerations. Should more attention be given to females? Patient Prefer Adherence (2016) 0.75
Management of Venous Thromboembolism: Recent Advances in Oral Anticoagulation Therapy. Ann Pharmacother (2016) 0.75
Net clinical benefit of dabigatran vs. warfarin in venous thromboembolism: analyses from RE-COVER(®), RE-COVER™ II, and RE-MEDY™. J Thromb Thrombolysis (2017) 0.75
Apixaban for oral antithrombotic therapy: is a new era coming? Mol Cell Ther (2014) 0.75
Major bleeding during secondary prevention of venous thromboembolism in patients who have completed anticoagulation: a systematic review and meta-analysis. J Thromb Haemost (2014) 0.75
Extended apixaban use for VTE. Nat Rev Cardiol (2013) 0.75
Analysis of the first therapeutic-target-achieving time of warfarin therapy and associated factors in patients with pulmonary embolism. Exp Ther Med (2016) 0.75
Development of New Deep Venous Thrombosis While on Apixaban. Case Rep Cardiol (2017) 0.75
Rendering factor Xa zymogen-like as a therapeutic strategy to treat bleeding. Curr Opin Hematol (2017) 0.75
Recent advances in the treatment of venous thromboembolism in the era of the direct oral anticoagulants. F1000Res (2017) 0.75
DVT Prevention in Stroke. Curr Neurol Neurosci Rep (2017) 0.75
Novel Anticoagulant Therapy of Venous Thromboembolism: Current Status and Future Directions. Ann Vasc Dis (2017) 0.75
Is it reasonable to use a lower DOACs dose in some patients with VTE? Yes. Intern Emerg Med (2017) 0.75
Predictive Value of Mean Platelet Volume for Pulmonary Embolism Recurrence. Lung (2017) 0.75
Oral rivaroxaban for the treatment of symptomatic pulmonary embolism. N Engl J Med (2012) 11.86
Oral rivaroxaban for symptomatic venous thromboembolism. N Engl J Med (2010) 9.92
Comparison of low-intensity warfarin therapy with conventional-intensity warfarin therapy for long-term prevention of recurrent venous thromboembolism. N Engl J Med (2003) 8.55
Edoxaban versus warfarin for the treatment of symptomatic venous thromboembolism. N Engl J Med (2013) 7.76
Edoxaban versus warfarin in patients with atrial fibrillation. N Engl J Med (2013) 7.70
Antithrombotic therapy for venous thromboembolic disease: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). Chest (2008) 7.12
Oral apixaban for the treatment of acute venous thromboembolism. N Engl J Med (2013) 7.00
Reversal of rivaroxaban and dabigatran by prothrombin complex concentrate: a randomized, placebo-controlled, crossover study in healthy subjects. Circulation (2011) 6.47
Antithrombotic therapy for venous thromboembolic disease: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. Chest (2004) 5.96
Idarucizumab for Dabigatran Reversal. N Engl J Med (2015) 5.91
Aspirin-resistant thromboxane biosynthesis and the risk of myocardial infarction, stroke, or cardiovascular death in patients at high risk for cardiovascular events. Circulation (2002) 5.79
Apixaban versus enoxaparin for thromboprophylaxis after hip replacement. N Engl J Med (2010) 5.59
Factor XI antisense oligonucleotide for prevention of venous thrombosis. N Engl J Med (2014) 4.58
Pulmonary arterial hypertension: baseline characteristics from the REVEAL Registry. Chest (2009) 4.08
Idraparinux versus standard therapy for venous thromboembolic disease. N Engl J Med (2007) 3.64
Parenteral anticoagulants: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). Chest (2008) 3.36
Apixaban versus enoxaparin for thromboprophylaxis in medically ill patients. N Engl J Med (2011) 3.30
Apixaban versus enoxaparin for thromboprophylaxis after knee replacement (ADVANCE-2): a randomised double-blind trial. Lancet (2010) 3.29
The changing picture of patients with pulmonary arterial hypertension in the United States: how REVEAL differs from historic and non-US Contemporary Registries. Chest (2010) 3.02
Apixaban or enoxaparin for thromboprophylaxis after knee replacement. N Engl J Med (2009) 2.90
New oral anticoagulants in atrial fibrillation and acute coronary syndromes: ESC Working Group on Thrombosis-Task Force on Anticoagulants in Heart Disease position paper. J Am Coll Cardiol (2012) 2.41
Oncogenic events regulate tissue factor expression in colorectal cancer cells: implications for tumor progression and angiogenesis. Blood (2004) 2.41
Oral thrombin inhibitor dabigatran etexilate vs North American enoxaparin regimen for prevention of venous thromboembolism after knee arthroplasty surgery. J Arthroplasty (2008) 2.30
Clinical utility of D-dimer in patients with suspected pulmonary embolism and nondiagnostic lung scans or negative CT findings. Chest (2004) 2.30
Non-vitamin K antagonist oral anticoagulants (NOACs): No longer new or novel. Thromb Haemost (2014) 2.29
Oral rivaroxaban versus standard therapy for the treatment of symptomatic venous thromboembolism: a pooled analysis of the EINSTEIN-DVT and PE randomized studies. Thromb J (2013) 2.21
Clinical features of paediatric pulmonary hypertension: a registry study. Lancet (2012) 2.13
Selective D-dimer testing for diagnosis of a first suspected episode of deep venous thrombosis: a randomized trial. Ann Intern Med (2013) 2.09
Comparative pharmacodynamics and pharmacokinetics of oral direct thrombin and factor xa inhibitors in development. Clin Pharmacokinet (2009) 2.07
Extended prophylaxis of venous thromboembolism with idraparinux. N Engl J Med (2007) 1.84
Breast cancer incidence in the randomized PEARL trial of lasofoxifene in postmenopausal osteoporotic women. J Natl Cancer Inst (2010) 1.79
An evaluation of D-dimer in the diagnosis of pulmonary embolism: a randomized trial. Ann Intern Med (2006) 1.78
Patients with severe sepsis vary markedly in their ability to generate activated protein C. Blood (2004) 1.67
The postthrombotic syndrome: evidence-based prevention, diagnosis, and treatment strategies: a scientific statement from the American Heart Association. Circulation (2014) 1.64
Further validation and simplification of the Wells clinical decision rule in pulmonary embolism. Thromb Haemost (2008) 1.61
Mechanism of catheter thrombosis: comparison of the antithrombotic activities of fondaparinux, enoxaparin, and heparin in vitro and in vivo. Blood (2011) 1.51
Translational success stories: development of direct thrombin inhibitors. Circ Res (2012) 1.49
Histidine-rich glycoprotein binds factor XIIa with high affinity and inhibits contact-initiated coagulation. Blood (2011) 1.48
New anticoagulants. Circulation (2010) 1.48
Prenatal exposure to the Dutch famine is associated with a preference for fatty foods and a more atherogenic lipid profile. Am J Clin Nutr (2008) 1.43
Screening for venous thrombosis by ultrasonography before hospital discharge after major joint surgery. Med J Aust (2005) 1.39
Vitamin K antagonists in heart disease: current status and perspectives (Section III). Position paper of the ESC Working Group on Thrombosis--Task Force on Anticoagulants in Heart Disease. Thromb Haemost (2013) 1.36
Design of the REVEAL registry for US patients with pulmonary arterial hypertension. Mayo Clin Proc (2008) 1.36
Design and rationale for RE-VERSE AD: A phase 3 study of idarucizumab, a specific reversal agent for dabigatran. Thromb Haemost (2015) 1.36
Assays for measuring rivaroxaban: their suitability and limitations. Ther Drug Monit (2010) 1.36
Strain history dependence of the nonlinear stress response of fibrin and collagen networks. Proc Natl Acad Sci U S A (2013) 1.35
Antiplatelet drugs: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest (2012) 1.31
Endogenous activated protein C limits cancer cell extravasation through sphingosine-1-phosphate receptor 1-mediated vascular endothelial barrier enhancement. Blood (2009) 1.23
A diagnostic strategy involving a quantitative latex D-dimer assay reliably excludes deep venous thrombosis. Ann Intern Med (2003) 1.21
New anticoagulants for treatment of venous thromboembolism. Arterioscler Thromb Vasc Biol (2008) 1.21
Vimentin exposed on activated platelets and platelet microparticles localizes vitronectin and plasminogen activator inhibitor complexes on their surface. J Biol Chem (2001) 1.21
Inferior vena cava ligation rapidly induces tissue factor expression and venous thrombosis in rats. Arterioscler Thromb Vasc Biol (2009) 1.19
Physician compliance with guidelines for deep-vein thrombosis prevention in total hip and knee arthroplasty. Curr Med Res Opin (2008) 1.18
Prognostic utility and characterization of cell-free DNA in patients with severe sepsis. Crit Care (2012) 1.18
Gastrointestinal bleeding with the new oral anticoagulants--defining the issues and the management strategies. Thromb Haemost (2013) 1.15
Oral direct factor Xa inhibition with edoxaban for thromboprophylaxis after elective total hip replacement. A randomised double-blind dose-response study. Thromb Haemost (2010) 1.14
New anticoagulants. Blood (2004) 1.13
Bivalent binding to gammaA/gamma'-fibrin engages both exosites of thrombin and protects it from inhibition by the antithrombin-heparin complex. J Biol Chem (2007) 1.13
Sensitivity and specificity of ultrasonography in the diagnosis of upper extremity deep vein thrombosis: a systematic review. Arch Intern Med (2002) 1.11
G-protein-coupled receptors as signaling targets for antiplatelet therapy. Arterioscler Thromb Vasc Biol (2008) 1.10
Contribution of host-derived tissue factor to tumor neovascularization. Arterioscler Thromb Vasc Biol (2008) 1.08
Oral direct factor Xa inhibitors. Circ Res (2012) 1.08
Antithrombotic therapy during percutaneous coronary intervention: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. Chest (2004) 1.07
Coagulation assays. Circulation (2005) 1.05
Plasma fibronectin supports hemostasis and regulates thrombosis. J Clin Invest (2014) 1.05
Evidence that both exosites on thrombin participate in its high affinity interaction with fibrin. J Biol Chem (2003) 1.05
Selective depletion of factor XI or factor XII with antisense oligonucleotides attenuates catheter thrombosis in rabbits. Blood (2014) 1.05
Influence of thrombophilia on risk of recurrent venous thromboembolism while on warfarin: results from a randomized trial. Blood (2008) 1.03
Modifications of evidence-based practices in community-based addiction treatment organizations: a qualitative research study. Addict Behav (2011) 1.03
Randomized trial of the effect of the low molecular weight heparin nadroparin on survival in patients with cancer. J Clin Oncol (2011) 1.02
HD1, a thrombin-directed aptamer, binds exosite 1 on prothrombin with high affinity and inhibits its activation by prothrombinase. J Biol Chem (2006) 1.01
Hypercoagulable states. Clin Chest Med (2010) 1.00
General mechanisms of coagulation and targets of anticoagulants (Section I). Position Paper of the ESC Working Group on Thrombosis--Task Force on Anticoagulants in Heart Disease. Thromb Haemost (2013) 0.99
Paediatric anticoagulation guidelines. S Afr Med J (2012) 0.95
Direct thrombin inhibitors in acute coronary syndromes: present and future. Circulation (2002) 0.95
Novel oral anticoagulants in gastroenterology practice. Gastrointest Endosc (2013) 0.94
Incorporation of vitronectin into fibrin clots. Evidence for a binding interaction between vitronectin and gamma A/gamma' fibrinogen. J Biol Chem (2001) 0.94
Treatment of venous thromboembolism in patients with cancer: subgroup analysis of the Matisse clinical trials. Thromb Haemost (2009) 0.94
Long range communication between exosites 1 and 2 modulates thrombin function. J Biol Chem (2009) 0.94